|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Expression of Interleukin-26 is upregulated in inflammatory bowel disease显示文摘AIM To investigate interleukin(IL)-26 expression in the inflamed mucosa of patients with inflammatory bowel disease(IBD) and the function of IL-26. METHODS Human colonic subepithelial myofibroblasts(SEMFs) were isolated from colon tissue surgically resected. The expression of IL-26 protein and its receptor complex was analyzed by immunohistochemistry. The gene expression induced by IL-26 was evaluated by realtime polymerase chain reaction. Intracellular signaling pathways were evaluated by immunoblotting and specific small interfering(si) RNA transfection. RESULTS The m RNA and protein expression of IL-26 were significantly enhanced in the inflamed mucosa of patients with IBD. IL-26 receptor complex was expressed in colonic SEMFs in vivo and in vitro. IL-26 stimulated the m RNA expression of IL-6 and IL-8 in colonic SEMFs. The inhibitors of mitogen-activated protein kinases and phosphoinositide 3-kinase, and si RNAs for signal transducers and activator of transcription 1/3, nuclear factor-kappa B and activator protein-1 significantly reduced the m RNA expression of IL-6 and IL-8 induced by IL-26.CONCLUSION These results suggest that IL-26 plays a role in the pathophysiology of IBD through induction of inflammatory mediators. | Makoto Fujii Atsushi Nishida Hirotsugu Imaeda Masashi Ohno Kyohei Nishino Shigeki Sakai Osamu Inatomi Shigeki Bamba Masahiro Kawahara Tomoharu Shimizu Akira Andoh | 2017 | World Journal of Gastroenterology2017，23，30： | 8 |
| 2 | Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?显示文摘Inflammatory bowel disease(IBD)is a chronic inflammatory condition of the gastrointestinal tract encompassing two main clinical entities,Crohn’s disease and ulcerative colitis.Accumulated evidence indicates that an aberrant immune activation caused by the interplay of genetic susceptibility and environmental impact on the gut microbiota may be involved in the pathogenesis of IBD.Rapid advances in next-generation sequencing technology have enabled a number of studies to identify the alteration of the gut microbiota,termed dysbiosis,in IBD.Moreover,the alteration in the metabolites derived from the gut microbiota in IBD has also been described in many studies.Therefore,microbiota-based interventions such as fecal microbiota transplantation(FMT)have attracted attention as a novel therapeutic option in IBD.However,in clinical trials,the efficacy of FMT for IBD remains controversial.Additional basic and clinical studies are required to validate whether FMT can assume a complementary role in the treatment of IBD.The present review provides a synopsis on dysbiosis in IBD and on the association between the gut microbiota and the pathogenesis of IBD.In addition,we summarize the use of probiotics in IBD and the results of current clinical trials of FMT for IBD. | Atsushi Nishida Kyohei Nishino Keitaro Sakai Yuji Owaki Yoshika Noda Hirotsugu Imaeda | 2021 | World Journal of Gastroenterology2021，27，23： | 6 |
| 3 | Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012显示文摘 | Hirotaka Ohara Kazuichi Okazaki Hirohito Tsubouchi Kazuo Inui Shigeyuki Kawa Terumi Kamisawa Susumu Tazuma Kazushige Uchida Kenji Hirano Hitoshi Yoshida Takayoshi Nishino Shigeru Ko Nobumasa Mizuno Hideaki Hamano Atsushi Kanno Kenji Notohara Osamu Hasebe | 2012 | Journal of Hepato-Biliary-Pancreatic Sciences2012，，5： | 3 |
| 4 | Establishment of a serum IgG 4 cut‐off value for the differential diagnosis of IgG 4‐related sclerosing cholangitis: A J apanese cohort显示文摘 | Hirotaka Ohara Takahiro Nakazawa Shigeyuki Kawa Terumi Kamisawa Tooru Shimosegawa Kazushige Uchida Kenji Hirano Takayoshi Nishino Hideaki Hamano Atsushi Kanno Kenji Notohara Osamu Hasebe Takashi Muraki Etsuji Ishida Itaru Naitoh Kazuichi Okazaki | 2013 | J Gastroenterol Hepatol2013，，7： | 2 |
| 5 | Capacitors: Operating principles,current market and technical trends显示文摘 | NISHINO ATSUSHI | 1996 | J Power Sources1996，60，2： | 1 |
| 6 | Characterization of activated carbon fiber cloths for electric double-layer capacitors by adsorption method显示文摘 | ICHIRO TANAHASHI AKIHIKO YOSHIDO ATSUSHI NISHINO | 1991 | Carbon1991，29，7： | 1 |
| 7 | Establishment of a serum IgG 4 cut‐off value for the differential diagnosis of IgG 4‐related sclerosing cholangitis: A J apanese cohort显示文摘 | Hirotaka Ohara Takahiro Nakazawa Shigeyuki Kawa Terumi Kamisawa Tooru Shimosegawa Kazushige Uchida Kenji Hirano Takayoshi Nishino Hideaki Hamano Atsushi Kanno Kenji Notohara Osamu Hasebe Takashi Muraki Etsuji Ishida Itaru Naitoh Kazuichi Okazaki | 2013 | J Gastroenterol Hepatol2013，，7： | 1 |
| 8 | Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012显示文摘 | Hirotaka Ohara Kazuichi Okazaki Hirohito Tsubouchi Kazuo Inui Shigeyuki Kawa Terumi Kamisawa Susumu Tazuma Kazushige Uchida Kenji Hirano Hitoshi Yoshida Takayoshi Nishino Shigeru Ko Nobumasa Mizuno Hideaki Hamano Atsushi Kanno Kenji Notohara Osamu Hasebe | 2012 | Journal of Hepato-Biliary-Pancreatic Sciences2012，，5： | 1 |
| 9 | Activated carbon fiber sheets as polarizable electrodes of electric double - layer capacitors显示文摘 | ICHIRO TANAHASHI AKIHIKO YOSHIDA ATSUSHI NISHINO | 1990 | Carbon1990，28，4： | 1 |
| 10 | Identific-ation of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Targ-et for Lung Cancer显示文摘 | Atsushi Takano Nobuhisa Ishikawa Ryohei Nishino | 2009 | Cancer Res2009，69，： | 1 |
| 11 | 显示文摘 | Atsushi Nishino | 1996 | Power Sources1996，60，26： | 1 |
| 12 | Update on gut microbiota in gastrointestinal diseases显示文摘The human gut is a complex microbial ecosystem comprising approximately 100 trillion microbes collectively known as the“gut microbiota”.At a rough estimate,the human gut microbiome contains almost 3.3 million genes,which are about 150 times more than the total human genes present in the human genome.The vast amount of genetic information produces various enzymes and physiologically active substances.Thus,the gut microbiota contributes to the maintenance of host health;however,when healthy microbial composition is perturbed,a condition termed“dysbiosis”,the altered gut microbiota can trigger the development of various gastrointestinal diseases.The gut microbiota has consequently become an extremely important research area in gastroenterology.It is also expected that the results of research into the gut microbiota will be applied to the prevention and treatment of human gastrointestinal diseases.A randomized controlled trial conducted by a Dutch research group in 2013 showed the positive effect of fecal microbiota transplantation(FMT)on recurrent Clostridioides difficile infection(CDI).These findings have led to the development of treatments targeting the gut microbiota,such as probiotics and FMT for inflammatory bowel diseases(IBD)and other diseases.This review focuses on the association of the gut microbiota with human gastrointestinal diseases,including CDI,IBD,and irritable bowel syndrome.We also summarize the therapeutic options for targeting the altered gut microbiota,such as probiotics and FMT. | Atsushi Nishida Kyohei Nishino Masashi Ohno Keitaro Sakai Yuji Owaki Yoshika Noda Hirotsugu Imaeda | 2022 | World Journal of Clinical Cases2022，10，22： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员